Details

Autor(en) / Beteiligte

• Schuepbach, W.M.M
• Rau, J
• Knudsen, K
• Volkmann, J
• Krack, P
• Timmermann, L
• Hälbig, T.D
• Hesekamp, H
• Navarro, S.M
• Meier, N
• Falk, D
• Mehdorn, M
• Paschen, S
• Maarouf, M
• Barbe, M.T
• Fink, G.R
• Kupsch, A
• Gruber, D
• Schneider, G.-H
• Seigneuret, E
• Kistner, A
• Chaynes, P
• Ory-Magne, F
• Brefel Courbon, C
• Vesper, J
• Schnitzler, A
• Wojtecki, L
• Houeto, J.-L
• Bataille, B
• Maltête, D
• Damier, P
• Raoul, S
• Sixel-Doering, F
• Hellwig, D
• Gharabaghi, A
• Krüger, R
• Pinsker, M.O
• Amtage, F
• Régis, J.-M
• Witjas, T
• Thobois, S
• Mertens, P
• Kloss, M
• Hartmann, A
• Oertel, W.H
• Post, B
• Speelman, H
• Agid, Y
• Schade-Brittinger, C
• Deuschl, G

Titel

Neurostimulation for Parkinson's Disease with Early Motor Complications

Ist Teil von

• The New England journal of medicine, 2013-02, Vol.368 (7), p.610-622

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In this 2-year trial involving patients with Parkinson's disease and early motor complications, subthalamic stimulation plus medical therapy resulted in better quality of life and motor function than medical therapy alone. Parkinson's disease is a progressive neurodegenerative disease that affects dopaminergic neurotransmission, resulting in bradykinesia, rigidity, and rest tremor. After an initial honeymoon period, during which there is a sustained response to dopaminergic treatment, beneficial effects are hampered by levodopa-induced motor complications, 1 progressively compromising quality of life. 2 – 4 Because levodopa-responsive parkinsonian symptoms are improved by high-frequency stimulation of the subthalamic nucleus, 5 , 6 neurostimulation has become an established treatment for advanced Parkinson's disease with medically intractable fluctuations and dyskinesia 7 – 10 and has shown long-term efficacy. 11 – 13 It is typically used after the disease has been present for 11 to 13 years, 7 – . . .